Challenges of combination therapy with immune checkpoint ...

Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-1) or its ligand (anti-PD-L1) is the backbone of numerous ...

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Ann-Lii Cheng1,2,*. , Chiun Hsu2,3,4,*. , Stephen L. Chan5 ...

Challenges of combination therapy with immune checkpoint ...

Other critical issues in the development of combination immunotherapy, including optimal management of immune-related adverse events and the value of ICI ...

Review Challenges of combination therapy with immune checkpoint ...

The most extensively tested combination regimens for advanced HCC comprise anti-PD-1/anti-PD-L1 agents plus antiangiogenic agents.

Prospects and challenges of CAR-T cell therapy combined with ICIs

Immune checkpoint inhibitors (ICIs) combined with CAR-T cell therapy is a novel combination therapy with high expectations to defeat solid tumors.

Challenges of combination therapy with immune checkpoint ...

Other critical issues in the development of combination immunotherapy, including optimal management of immune-related adverse events and the value of ICI ...

Immune checkpoint inhibitor combinations—current and emerging ...

Immune checkpoint inhibitors (ICI) have changed the oncology treatment landscape since their initial approval in melanoma. While there is much ...

Checkpoint therapy in cancer treatment: progress, challenges, and ...

Finally, utilizing ICB in the neoadjuvant setting has shown substantial tumor shrinkage, enhanced immune responses, and improved surgical ...

Using Combination therapy to overcome diverse challenges of ...

Immune checkpoint inhibitors (ICIs) have heralded a new era in immunotherapy, representing a pivotal breakthrough in cancer treatment.

The combination of immune checkpoint inhibitors and antibody-drug ...

This article reviewed phase 2 and 3 clinical studies of ICIs, ADCs, and their combination in the treatment of urogenital tumors to highlight safe and effective ...

Clinical Challenges of Immune Checkpoint Inhibitors: Cancer Cell

On the one hand, ICIs lead to challenging patterns of toxicity and efficacy, very different to those from classical chemotherapy or targeted ...

Immune Checkpoint Inhibitor Combinations in Solid Tumors

Potential synergistic combinations include checkpoint blockade with conventional (radiation, chemotherapy and targeted therapies) and newer immunotherapies.

Combination immunotherapy: a road map

The model, however, has numerous limitations, including the lack of appropriate tumor microenvironment, potential problems with limited host immune system ...

The adverse events associated with combination immunotherapy in ...

Treatment with immune-checkpoint inhibitors promotes the expansion of activated T cells, resulting in enhanced tumor cell recognition and ...

Combining Immune Checkpoint Inhibitors With Conventional Cancer ...

Chemotherapy in combination with immunotherapy (CIT) has been studied in multiple solid tumors, largely in NSCLC, providing broadened treatment options with ...

Next generation of immune checkpoint therapy in cancer

In cancer, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response. Immune checkpoint therapies act by ...

Immune checkpoint therapy—current perspectives and future ...

Furthermore, ICT can lead to the development of immune-related adverse events (irAEs) that can prove to be fatal in a fraction of patients. In ...

[PDF] Combination therapy with immune checkpoint inhibitors (ICIs)

The therapeutic benefits of ICIs as a groundbreaking approach in the context of tumor immunotherapy are focused on and the therapeutic influences of the ...

Immunotherapies and Combination Strategies for Immuno-Oncology

To overcome this challenge, combination therapy with multiple immune checkpoint inhibitors is frequently studied [11]. However, research is also underway to ...

Using Combination therapy to overcome diverse challenges of ...

PDF | Immune checkpoint inhibitors (ICIs) have heralded a new era in immunotherapy, representing a pivotal breakthrough in cancer treatment.